NCNA
NuCana PLCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$8.49M
P/E Ratio
0.00
EPS
$0.00
Beta
1.80
52W High
$250.00
52W Low
$1.33
50-Day MA
$1.95
200-Day MA
$3.82
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About NuCana PLC
NuCana plc, a clinical-stage biopharmaceutical company, is dedicated to the development of products for the treatment of cancer. The company is headquartered in Edinburgh, the United Kingdom.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-20.60M |
| Operating Margin | 0.00% |
| Return on Equity | -193.90% |
| Return on Assets | -58.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.91 |
| Price-to-Book | 0.26 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.30 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $4.16M |
| Float | $20.81B |
| % Insiders | 0.00% |
| % Institutions | 4.08% |
Historical Volatility
HV 10-Day
72.54%
HV 20-Day
104.31%
HV 30-Day
96.87%
HV 60-Day
87.85%
HV Rank
—
Volatility is currently contracting
Data last updated: 4/30/2026